Hematological Malignancies

Oncology·MeSH: Lymphoma, Non-Hodgkin

18 drugs in development·15 companies·9 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Imbruvica	Royalty Pharma plc (RPRX)

Phase 3(3)

Phase 2(1)

Drug	Company
cnct19	CASI Pharmaceuticals, Inc (DE) (CASI)

Phase 1(6)

Drug	Company
apg-3288	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
bi-1206	CASI Pharmaceuticals, Inc (DE) (CASI)
ft839	FATE THERAPEUTICS INC (FATE)
narazaciclib	TRAWS PHARMA, INC. (ONTX)
plogosertib (plogo)	Bio Green Med Solution, Inc. (BGMSP)
tuspetinib	Aptose Biosciences Inc. (APTOF)

Preclinical(6)

Drug	Company
adp-520	Adaptimmune Therapeutics PLC (ADAP)
car-based product candidate targeting egfrviii	Kite Pharma, Inc. (KITE)
duet-03	Scopus BioPharma Inc. (SCPS)
onc212	CHIMERIX INC (CMRX)
tcr-based product candidates targeting ssx2	Kite Pharma, Inc. (KITE)
Veto Cell technology	Cell Source, Inc. (CLCS)

Phase 1/Phase 2(1)

Drug	Company
cpi-0209	CONSTELLATION PHARMACEUTICALS INC (CNST)

BioSniper tracks 18 drugs in development for Hematological Malignancies across 15 companies.

There are 9 clinical trials targeting Hematological Malignancies tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.